Share
December 11, 2020 The Russian branch of pharmaceutical giant AstraZeneca has stated that it plans to use part of the Russian Sputnik V vaccine in future clinical trials.
"Today we announce a clinical trial program to evaluate the safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University, and the Sputnik V vaccuno, developed by the Russian research institute Gamaleya," says AstraZeneca in a statement published on its website.
Data released this week showed that AstraZeneca's vaccine, under development together with the University of Oxford, has an average efficacy of 70.4%, based on an aggregate analysis of interim data from studies in advanced stage. According to the Russian side, the preliminary results of the clinical trial of the Sputnik V vaccine showed its efficacy above 90%, on November 23, 2020. The Russian Direct Investment Fund and the Gamaleya Institute offered AstraZeneca to use the two components (human adenoviral vectors1) of the Sputnik V vaccine in AstraZeneca clinical trials. "AstraZeneca has accepted - according to the Fund - the proposal and will begin clinical trials of its vaccine in combination with Sputnik V type Ad26 human adenoviral vector by the end of 2020. This research will allow AstraZeneca scientists to investigate the possibility of increase the effectiveness of their vaccine through the application of this combined approach. "